RecruitingPhase 2 / Phase 3NCT07176546
Immune
ANCA-Associated Vasculitis
Also known as AAV, granulomatosis with polyangiitis, GPA, MPA
ANCA-Associated Vasculitis encompasses granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA), unified by neutrophil-activating autoantibodies targeting proteinase 3
ORPHA:156152 ↗Prevalence 150-300 in 1,000,000Onset Middle to older adulthood; peak in 6th-7th decadeSmall vessel systemic vasculitis (ANCA mediated)
73
studies recruiting now
as of 7 Sept 2026
274
studies registered in total
as of 7 Sept 2026
13
countries with a recruiting site
as of 7 Sept 2026
2 Sept 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1 / Phase 2NCT07800871
FT839 in Autoimmune Diseases
RecruitingNCT00315380
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
RecruitingPhase 3NCT06512883
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
RecruitingNCT07251179
Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 73 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new ANCA-Associated Vasculitis study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: VCRC Patient Contact Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About ANCA-Associated Vasculitis
ANCA-Associated Vasculitis encompasses granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA), unified by neutrophil-activating autoantibodies targeting proteinase 3 (PR3-ANCA) or myeloperoxidase (MPO-ANCA), causing necrotizing inflammation of small to medium vessels. Renal involvement with rapidly progressive glomerulonephritis and pulmonary manifestations including alveolar hemorrhage are the most immediately life-threatening features. Rituximab and cyclophosphamide have equivalent efficacy for induction, while avacopan (a C5a receptor inhibitor) has received approval as a steroid-sparing agent.
Common clinical features
Rapidly progressive glomerulonephritis with hematuria and castsPulmonary capillaritis with alveolar hemorrhageSino-nasal destruction (saddle-nose, chronic otitis in GPA)Peripheral neuropathy (mononeuritis multiplex)Orbital pseudotumor and proptosis (GPA)Asthma and peripheral eosinophilia (EGPA)Purpura and cutaneous ulceration
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
1 approved treatment and 2 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Avacopan (Tavneos)
Phase 2Tarperprumig
Phase 2Ruxoprubart
Before you apply
Things trial teams commonly ask about for ANCA-Associated Vasculitis. Not eligibility rules; those are set by each study.
- ANCA serotype (PR3 vs MPO) and AAV subtype (GPA, MPA, EGPA) determine trial eligibility; many trials enroll specific subtypes only — know your ANCA titer and subtype before applying
- Avacopan and other complement-targeting trials require documented active disease with BVAS score confirmation; inactive or remission-phase patients are not eligible for induction trials
- Renal function trajectory (eGFR trend, dialysis dependence) critically affects eligibility; dialysis-dependent patients may be excluded from some trials while specifically enrolled in others
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).